Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436992 | 1.00 | TMEM97 (0.42) | TMEM97SIGMAR1ROCK2SMN1; SMN2CYP3A4 | |
| SCHEMBL8177012 | 0.97 | NAAA (0.42) | TMEM97SIGMAR1ROCK2SMN1; SMN2CYP3A4 | |
| SCHEMBL8177015 | 0.97 | NAAA (0.42) | TMEM97SIGMAR1ROCK2SMN1; SMN2CYP3A4 | |
| SCHEMBL8192360 | 0.97 | NAAA (0.43) | TMEM97SIGMAR1ROCK2CYP3A4PAK4 | |
| SCHEMBL1116349 | 0.97 | NAAA (0.43) | TMEM97SIGMAR1ROCK2CYP3A4PAK4 | |
| SCHEMBL8192365 | 0.97 | NAAA (0.43) | TMEM97SIGMAR1ROCK2CYP3A4PAK4 | |
| SCHEMBL1116363 | 0.97 | NAAA (0.43) | TMEM97SIGMAR1ROCK2CYP3A4PAK4 | |
| SCHEMBL6985636 | 0.95 | ROCK2 (0.42) | TMEM97SIGMAR1ROCK2CYP3A4PAK4 | |
| SCHEMBL6985634 | 0.95 | ROCK2 (0.42) | TMEM97SIGMAR1ROCK2CYP3A4PAK4 | |
| SCHEMBL8176218 | 0.92 | TDP1 (0.41) | TMEM97SIGMAR1SMN1; SMN2PAK4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2826480-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | Boehringer Ingelheim International GmbH (DE) | 2015-01-21 | — | — | EP | claimed |
| EP-2409705-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-25 | — | — | EP | claimed |
| EP-2361626-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-31 | — | — | EP | claimed |
| EP-2359829-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-24 | — | — | EP | claimed |
| JP-4701159-B2 | — | — | 2011-06-15 | — | — | JP | claimed |
| EP-2281561-A2 | Use of LCK inhibitors for treatment of immunologic diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-02-09 | — | — | EP | claimed |
| US-20090306104-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | claimed |
| US-20090087405-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-02 | — | — | US | claimed |
| US-20080254040-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | claimed |
| JP-2006524634-A | — | — | 2006-11-02 | — | — | JP | claimed |
| EP-1622619-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | Boehringer Ingelheim International GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| EP-1530466-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | Boehringer Ingelheim Pharma KG (DE) | 2005-05-18 | — | — | EP | claimed |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| WO-2004096224-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | WO | claimed |
| US-20040204458-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-14 | — | — | US | claimed |
| WO-2004017948-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | claimed |
| WO-2000073297-A1 | SUBSTITUTED INDOLINONE AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-12-07 | — | — | WO | claimed |
| US-20150265610-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20040204458-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-14 | — | — | US | disclosed |
| WO-2000073297-A1 | SUBSTITUTED INDOLINONE AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080254040-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS OR ANGIOGENESIS | BAX, BCL2, CXCL12 | TMEM97 3854/4885SIGMAR1 4726/4885ROCK2 410/4885 |
| US-20150265610-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BAX, BCL2, VEGFA | TMEM97 3716/4885SIGMAR1 4685/4885ROCK2 435/4885 |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BAX, BCL2, CXCL12 | TMEM97 3854/4885SIGMAR1 4726/4885ROCK2 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.